文献速递传染病防控与疫情报告

非昔硝唑作为布氏锥虫罗得西亚亚种所致人类非洲锥虫病的新型口服治疗:一项前瞻性、开放标签、单臂、2-3期、非随机研究

Fexinidazole as a new oral treatment for human African trypanosomiasis due to Trypanosoma brucei rhodesiense: a prospective, open-label, single-arm, phase 2-3, non-randomised study.
PubMed 文献 · Lancet Glob Health · 2025-01-01

这项在乌干达和马拉维两个中心开展的前瞻性、开放标签、单臂、2-3期、非随机研究纳入45例罗得西亚人类非洲锥虫病患者(35例2期,10例1期),口服非昔硝唑10天并随访12个月。2期患者住院结束时病死率为0%(34例中0例,90%CI 0-8.43),低于预设的8.5%(p=0.0488)。非昔硝唑是安全且易于使用的治疗,是现有治疗(美拉胂醇或苏拉明)的更好替代。

要点

  • 2期罗得西亚人类非洲锥虫病住院结束时病死率为0%(34例中0例,90%CI 0-8.43),低于预设8.5%(p=0.0488)。
  • 1期患者未见治疗失败,2期患者中1例在第9周复发。
  • 基于标准评估和心电图未发现非预期安全性信号。

核心结论

  • 非昔硝唑是安全且易于使用的治疗,是罗得西亚人类非洲锥虫病现有治疗(如美拉胂醇或苏拉明)的更好替代。

研究设计与样本

  • 前瞻性、开放标签、单臂、2-3期、非随机研究,在乌干达Lwala和马拉维Rumphi两个中心开展。
  • 纳入年龄6岁及以上、体重20 kg及以上、寄生虫学确诊罗得西亚人类非洲锥虫病、能随餐吞服非昔硝唑片剂且Karnofsky评分40及以上的患者;妊娠或哺乳女性在妊娠前三个月后符合条件。
  • 住院期间按体重推荐剂量口服非昔硝唑10天,随访12个月;共筛查46例,纳入并治疗45例(35例2期,10例1期)。
  • 主要终点为2期患者住院结束时病死率(仅计可能与疾病或非昔硝唑相关的死亡),与基于文献的预设8.5%比较。
  • 研究注册号ClinicalTrials.gov NCT03974178;研究时间为2019年9月29日至2022年10月12日。

主要发现

  • 2期患者住院结束时病死率为0%(34例中0例,90%CI 0-8.43),低于预设8.5%(p=0.0488)。
  • 治疗期间发生1例死亡,但被认为与罗得西亚人类非洲锥虫病或非昔硝唑无关,未纳入疗效分析。
  • 1例2期患者在第9周复发;1期患者未见治疗失败。
  • 基于标准评估和心电图未发现非预期安全性信号。

临床怎么用

  • 作者认为非昔硝唑是安全且易于使用的治疗,是罗得西亚人类非洲锥虫病现有治疗(如美拉胂醇或苏拉明)的更好替代。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rhodesiense human African trypanosomiasis is a neglected disease with epidemic potential that can rapidly become lethal if left untreated. The aim of this study was to show that fexinidazole could offer an alternative to existing treatments (melarsoprol for stage 2 and suramin for stage 1 rhodesiense human African trypanosomiasis), using a benchmark study design. METHODS: This was a prospective, open-label, single-arm, phase 2-3, non-randomised study done in two centres (Lwala, Uganda and Rumphi, Malawi). Participants were enrolled if they were aged 6 years or older, weighed 20 kg or more, had parasitologically confirmed rhodesiense human African trypanosomiasis, were able to swallow fexinidazole tablets with a meal, and had a Karnofsky score of 40 or more. Pregnant or breastfeeding women were eligible after the first trimester of pregnancy. While admitted to hospital, participants received oral fexinidazole for 10 days at the recommended dosage according to bodyweight and were followed up for 12 months. The fatality and non-response to treatment rates observed with fexinidazole were compared with predefined rates based on literature. The primary endpoint was the fatality rate at end of hospital admission (EoH) in participants with stage 2 rhodesiense human African trypanosomiasis (considering only deaths possibly related to the disease or fexinidazole), to be compared with 8·5%, an approximation of the fatality rate obtained with melarsoprol. This study is registered with ClinicalTrials.gov, NCT03974178. FINDINGS: Between Sept 29, 2019, and Oct 12, 2022, 46 participants with rhodesiense human African trypanosomiasis were screened, of whom 45 were included and treated (35 with stage 2 and ten with stage 1 disease). One death occurred during treatment but was considered unrelated to rhodesiense human African trypanosomiasis or fexinidazole and excluded from the efficacy analysis. No other deaths had occurred by EoH in participants with stage 2 rhodesiense human African trypanosomiasis, giving a fatality rate of 0 (0%) of 34 (90% CI 0-8·43), which was lower than the predefined 8·5% rate (p=0·0488). One participant with stage 2 rhodesiense human African trypanosomiasis had a relapse at week 9. No failures were reported in participants with stage 1 rhodesiense human African trypanosomiasis. No unexpected safety signals were identified on the basis of standard assessments and electrocardiograms. INTERPRETATION: Fexinidazole is a safe and easy-to-use treatment, and is a better-accepted alternative to existing treatments for rhodesiense human African trypanosomiasis, such as melarsoprol or suramin. FUNDING: EDCTP and various donors through the Drugs for Neglected Diseases initiative.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Matovu E, Nyirenda W, Eriatu A, et al. Fexinidazole as a new oral treatment for human African trypanosomiasis due to Trypanosoma brucei rhodesiense: a prospective, open-label, single-arm, phase 2-3, non-randomised study. Lancet Glob Health. 2025. PMID: 40288400. doi:10.1016/S2214-109X(25)00016-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。